Drugs / P16_37-63
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02526316 | Jun 2015 → May 2017 | virus associated tumor | Oryx GmbH & Co. KG | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01462838 | Aug 2011 → Jan 2015 | virus associated tumor | Oryx GmbH & Co. KG | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P16_37-63 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02526316 ↗ |
| Known as | p16INK4a-37-63 | “The p16INK4a-peptide (p16INK4a-37-63, 100 mcg) mixed with MONTANIDE ISA-51 VG (0.3 ml) will be administered subcutaneously once weekly for four weeks, followed by a 4-week rest...” NCT02526316 ↗ |
| Modality | Peptide | “P16\_37-63 -peptide” NCT01462838 ↗ |
| Route | Subcutaneous | “100 ug per application subcutaneously” NCT01462838 ↗ |